[go: up one dir, main page]

Dou et al., 2021 - Google Patents

The immune landscape of Chinese head and neck adenoid cystic carcinoma and clinical implication

Dou et al., 2021

View HTML
Document ID
7660534200799636347
Author
Dou S
Li R
He N
Zhang M
Jiang W
Ye L
Yang Y
Zhao G
Yang Y
Li J
Chen D
Zhu G
Publication year
Publication venue
Frontiers in Immunology

External Links

Snippet

Novel systemic agents and effective treatment strategies for recurrence adenoid cystic carcinoma (ACC) of the head and neck are still worthy of further exploration. Here, we analyzed the mutations and expression profiles of 75 Chinese ACC patients, characterized …
Continue reading at www.frontiersin.org (HTML) (other versions)

Classifications

    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay
    • G01N33/574Immunoassay; Biospecific binding assay for cancer
    • G01N33/57407Specifically defined cancers
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5011Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES OR MICRO-ORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or micro-organisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68Measuring or testing processes involving enzymes, nucleic acids or micro-organisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876Hybridisation probes
    • C12Q1/6883Hybridisation probes for diseases caused by alterations of genetic material
    • C12Q1/6886Hybridisation probes for diseases caused by alterations of genetic material for cancer

Similar Documents

Publication Publication Date Title
Zhu et al. Molecular correlates of clinical response and resistance to atezolizumab in combination with bevacizumab in advanced hepatocellular carcinoma
Chocarro de Erauso et al. Resistance to PD-L1/PD-1 blockade immunotherapy. A tumor-intrinsic or tumor-extrinsic phenomenon?
Lim et al. The molecular and functional landscape of resistance to immune checkpoint blockade in melanoma
Arora et al. Existing and emerging biomarkers for immune checkpoint immunotherapy in solid tumors
Hodi et al. TMB and inflammatory gene expression associated with clinical outcomes following immunotherapy in advanced melanoma
Genova et al. Therapeutic implications of tumor microenvironment in lung cancer: focus on immune checkpoint blockade
Lee et al. Transcriptional downregulation of MHC class I and melanoma de-differentiation in resistance to PD-1 inhibition
Daniels et al. Cellular origins and genetic landscape of cutaneous gamma delta T cell lymphomas
Jessurun et al. Biomarkers for response of melanoma patients to immune checkpoint inhibitors: a systematic review
Leruste et al. Clonally expanded T cells reveal immunogenicity of rhabdoid tumors
Friedman et al. Atezolizumab treatment of tumors with high tumor mutational burden from MyPathway, a multicenter, open-label, phase IIa multiple basket study
Conforti et al. Sex-based dimorphism of anticancer immune response and molecular mechanisms of immune evasion
Kemp et al. Pancreatic cancer is marked by complement-high blood monocytes and tumor-associated macrophages
Lo et al. Epitope spreading toward wild-type melanocyte-lineage antigens rescues suboptimal immune checkpoint blockade responses
Wang et al. Mechanism of immune evasion in breast cancer
Dou et al. The immune landscape of Chinese head and neck adenoid cystic carcinoma and clinical implication
Weeden et al. Early immune pressure initiated by tissue-resident memory T cells sculpts tumor evolution in non-small cell lung cancer
Soulieres et al. Molecular alterations and buparlisib efficacy in patients with squamous cell carcinoma of the head and neck: biomarker analysis from BERIL-1
Galsky et al. Immunomodulatory effects and improved outcomes with cisplatin-versus carboplatin-based chemotherapy plus atezolizumab in urothelial cancer
Alvarez-Prado et al. Immunogenomic analysis of human brain metastases reveals diverse immune landscapes across genetically distinct tumors
Wang et al. Progression of EGFR-mutant lung adenocarcinoma is driven by alveolar macrophages
Raskova Kafkova et al. NSCLC: from tumorigenesis, immune checkpoint misuse to current and future targeted therapy
Iafolla et al. Predicting toxicity and response to pembrolizumab through germline genomic HLA class 1 analysis
Huang et al. Identification of immune-related subtypes and characterization of tumor microenvironment infiltration in bladder cancer
Sun et al. Construction of a promising tumor-infiltrating CD8+ T cells gene signature to improve prediction of the prognosis and immune response of uveal melanoma